Current Challenges in AI Drug Development

Xiao Huang:DOORM, what challenges does AI drug development currently face? Why is it said that it has not yet entered its golden age?

DOORM:Despite the enormous potential of AI in drug development, it still faces several challenges. Firstly, although there has been significant investment, the actual output has not yet materialized, with many new drugs still in clinical trials and not yet marketed. Secondly, the market performance of the first AI drug has been poor, limiting investor confidence. Additionally, the application of AI technology in drug development requires more clinical validation and regulatory approval. Therefore, although the prospects are promising, AI drug development has not yet entered its golden age and requires more time and effort to realize its potential.